Recent data show children who received a booster dose of MenACWY-CRM following primary immunization with either MenACWY-CRM-D or MenACWY-D had strong immune responses 2 years after vaccination.
Roger Baxter, MD, of Kaiser Permanente Vaccine Study Center in Oakland, Calif., and colleagues assigned children aged 19.2±2.3 years to groups according to whether they had previously received primary vaccination with MenACWY-CRM (Menveo, Novartis) (n=131) or MenACWY-CRM-D (Menactra, Sanofi Pasteur) (n=76); a booster dose of MenACWY-CRM 3 years after primary vaccination with MenACWY-CRM (n=44) or MenACWY-D (n=31); or no vaccination (n=107). Human complement serum bactericidal activity (hSBA) was assessed for serogroups A, C, W and Y. The study was conducted from February 2009 to November 2012.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.